Ayşegül Atmaca

Ayşegül Atmaca

Auto-generated profile, based on publicly available information

Ayşegül Atmaca

Endocrinology Department, Ondokuz Mayıs University, Samsun, Turquie

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2021 in Postgraduate Medicine
Verified
Journal Article
Closed access
NYNarimana Imanova Yaghji
Narimana Imanova Yaghji
EKElif Kilic Kan
Elif Kilic Kan
SASongul Akcan
Songul Akcan
RCRamis Colak
Ramis Colak
AAAysegul Atmaca
Aysegul Atmaca
Hypoglycemia is a serious adverse effect of hydroxychloroquine (HCQ) which is very rare in non-diabetic patients. This case report describes a non-diabetic patient without any other chronic diseases, who experienced mild hypoglycemia related to HCQ used for COVID-19 treatment. All etiologies causing hypoglycemia were investigated and a 72-hour fast test was performed. A 34-years old male patient was admitted to our hospital with a high fever, cough, and chest pain. The result of his COVID-19 PCR test was positive. He received HCQ for 10 days for the treatment of COVID-19 infection. He experienced fatigue, dizziness, severe headache, weakness and feeling of hunger after discontinuation of HCQ during his isolation at home. Before COVID-19 infection, he never experienced hypoglycemia symptoms. He did not have a history of chronic diseases, drug use, alcohol consumption or smoking. A Seventy two-hour fasting test was performed. He complained about headache and weakness during the 72 hours test period. The PG level was determined as 49 mg/dl during these symptoms. Concurrent insulin and C-peptide levels were <2 mU/mL and 0.553 ng/mL, respectively. ACTH, cortisol, growth hormone, liver and kidney function tests were normal. HbA1c level was 4.7% (28 mmol/mol) (Normal Range %4,5-5,7). Hypoglycemia may be observed as an adverse effect of HCQ used for COVID-19 infection even in patients without chronic diseases and comorbidities. We must be careful while using HCQ for these patients and must warn them about this effect. The warning about hypoglycemia effect of HCQ must be added to COVID-19 treatment guidelines.

1 July 2021 in European Journal of Rheumatology
Verified
Journal Article
Open access
FSFulden Saraç
Fulden Saraç
AGAlper Gürlek
Alper Gürlek
ASAlev Selek
Alev Selek
ODOğuzhan Deyneli
Oğuzhan Deyneli
EAErsin Akarsu
Ersin Akarsu
SSsemra aytürk salt
semra aytürk salt
Objective: Paget disease of bone (PDB) is a metabolic bone disease that has been rarely reported in the Eastern countries. This study aimed to evaluate the clinical and demographic characteristics of patients with PDB followed up at endocrinology clinics in Turkey. Methods: An invitation was sent to tertiary endocrinology clinics to complete a survey on the demographic, clinical, radiological, and laboratory parameters, as well as treatment modalities of patients with PDB. This study enrolled clinically and radiologically proven 185 patients with PDB from 18 endocrinology centers based in 10 cities of Turkey. Results: This cohort of PDB had female preponderance (women/men: 105/80) with a mean age, during diagnosis, of 57±10 years. Most of the patients (59.6%) were symptomatic at diagnosis. Bone pain and headache were the predominant clinical symptoms. Polyostotic disease was observed in 67.5% (n=125) of patients. Frequently affected bones were skull (41.6%), pelvis (53.5%), spine (41%), and femur (25.4%). Moreover, 17 patients with skull involvement had hearing loss. Mean serum alkaline phosphatase (ALP) level (552±652 IU/L; range: 280-5762 IU/L) was over the normal reference cutoff with normal serum calcium levels. Intravenous bisphosphonates (zoledronic acid, 5 mg; pamidronate, 60-90 mg) were the most used drugs (75%) for the treatment of PDB. Most of the patients (87.1%) treated with intravenous bisphosphonates responded well, with a decrease in serum ALP level (117±114 IU/L) in the 12th month of therapy. Furthermore, 16 patients relapsed after the second year of therapy; 3 patients did not respond to the initial intravenous bisphosphonate treatment. Conclusion: The patients with PDB followed up by endocrinology clinics of Turkey exhibited polyostotic disease with classical clinical, radiological, and biochemical features and women’s predominance with good response to intravenous bisphosphonate therapy. Cite this article as: Gogas Yavuz D, Aytürk S, Çetinkalp Ş, Bayraktar F, Kulaksızoğlu M, Hekimsoy Z, et al. Clinical and demographic aspects of Paget disease of bone: A multicentric study from Turkey. Eur J Rheumatol 2021; 8(3): 156-61.

24 September 2022 in Annales d'Endocrinologie
Verified
Journal Article
Closed access
NDN. Driessens
N. Driessens
LNL. Nieman
L. Nieman
MBM. Boscaro
M. Boscaro
CSC. Scaroni
C. Scaroni
TDT. Deutschbein
T. Deutschbein
MTM. Tóth
M. Tóth

1 April 2020 in Üroonkoloji Bülteni
Verified
Journal Article
Closed access
EKElif Kılıç Kan
Elif Kılıç Kan
EÖEnder Özden
Ender Özden
AAAyşegül Atmaca
Ayşegül Atmaca
RÇRamis Çolak
Ramis Çolak